The Role of Endothelin-1 in Sickle Cell Disease

Phase 1 Completed 26 enrolled Augusta University Gilead Sciences · collab National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary goal of the study is to determine the safety and tolerability of ambrisentan. It is also expected that ambrisentan will improve blood flow in the lungs, decrease inflammation, and reduce pain in sickle cell patients. An additional goal is to evaluate the use of select biomarkers in evaluating sickle nephropathy.

Timeline

Start: 2015-09
Primary completion: 2019-05-30
Completion: 2019-11-30

Publications

Obadina M, Wilson S, Derebail VK, Little J. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations. Kidney360. 2023 Jul 1;4(7):997-1005. doi: 10.34067/KID.0000000000000162. Epub 2023 May 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ambrisentan	Small molecule	5 mg	Oral

The Role of Endothelin-1 in Sickle Cell Disease

Summary

Timeline

Publications

Drugs

Indications